Clonidine and Trazodone for Sleep Initiation: Guidelines and Recommendations

Introduction to Sleep Initiation Guidelines

The American Academy of Sleep Medicine explicitly recommends against using trazodone for sleep onset insomnia (WEAK recommendation) 1, 2
The VA/DOD guidelines explicitly advise against trazodone use due to its adverse effect profile outweighing low-quality efficacy evidence 3

Trazodone 50 mg reduced sleep latency by only a minimal amount compared to placebo, which falls below the threshold for clinical significance 1, 2
Total sleep time increased by a clinically insignificant amount 1, 2
Sleep quality showed no significant improvement versus placebo 1, 2
The overall quality of evidence was moderate, with the task force determining that harms potentially outweigh benefits 1, 2
75% of trazodone subjects experienced adverse events compared to a lower percentage on placebo 1, 2
Headache and somnolence occurred more frequently in trazodone subjects than in placebo subjects 1, 2

No major sleep medicine guidelines recommend clonidine for the treatment of chronic insomnia disorder in adults 1, 2, 3, 5
Clonidine is not mentioned in the American Academy of Sleep Medicine's 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia 1, 2
The VA/DOD 2019 guidelines do not include clonidine among recommended or evaluated agents for insomnia treatment 3

Cognitive Behavioral Therapy for Insomnia (CBT-I) should be first-line treatment 3, 5
Zolpidem 10 mg is recommended by the American Academy of Sleep Medicine for sleep onset insomnia 5
Zaleplon 10 mg is specifically recommended for sleep onset only 5
Ramelteon 8 mg is recommended for sleep onset insomnia 5
Eszopiclone 2-3 mg is recommended for both sleep onset and maintenance 5
Triazolam 0.25 mg is recommended for sleep onset only 5
All hypnotics should be prescribed at the lowest effective dose and shortest possible duration 3, 5
Patients must be counseled about risks of complex sleep behaviors associated with benzodiazepine receptor agonists 3

Implement non-pharmacologic interventions (CBT-I components) as the first step 3, 5
If pharmacotherapy is needed, choose from FDA-approved hypnotics based on patient factors 5
Regular follow-up every few weeks initially to assess effectiveness, adverse effects, and ongoing need 5
Taper medication when conditions allow; do not continue indefinitely without reassessment 5

Do not use trazodone or clonidine as first-line therapy for primary insomnia 5
Do not prescribe sedating medications without first attempting CBT-I or FDA-approved hypnotics 5
Do not use over-the-counter antihistamines due to tolerance and anticholinergic risks 3
Do not use antipsychotics for insomnia due to sparse evidence and significant harms 3
Do not use benzodiazepines due to risks of dependency, falls, cognitive impairment, and respiratory depression 3